Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycemia
Diabetes, Obesity and Metabolism Feb 15, 2019
Aronson R, et al. - Data from the LixiLan-O trial was assessed to study the impact of insulin glargine (iGlar)/lixisenatide (Lixi) fixed-ratio combination on glycaemic variability (GV) and control without increasing hypoglycemia. They measured the GV features including mean and SD of self-measured plasma glucose (SMPG), high blood glucose index (HBGI) and low blood glucose index, area under the SMPG curve for each candidate (AUCn), mean absolute glucose (MAG) and mean amplitude of glycaemic excursions (MAGE). They observed an improvement in all GV markers from baseline by week 30, with no incline in hypoglycemia risk while using iGlarLixi. They noticed significant improvements in SMPG, SD of SMPG, HBGI, AUCn, MAG and MAGE as compared to iGlar, and in SMPG, HBGI and AUCn, in comparison with Lixi.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries